The U.S. Food and Drug Administration (FDA) is expediting the development of new treatments for mental illness by awarding priority review vouchers to three companies researching psychedelic drugs. This action follows a directive from former President Donald Trump, aimed at streamlining the approval process for promising therapies.

Priority Review Vouchers Explained

These vouchers can significantly reduce the FDA review timeline for new drugs, potentially shortening it from six to ten months to as little as one to two months. This expedited process aims to bring potentially life-changing medications to market faster.

Companies Receiving Vouchers

Compass Pathways has confirmed receiving a voucher for COMP360, its synthetic psilocybin formulation for treatment-resistant depression. Usona Institute is investigating psilocybin for major depressive disorder, and Transcend Therapeutics is exploring methylone for post-traumatic stress disorder (PTSD). While the FDA has identified these companies, official confirmation from Usona and Transcend is still pending.

Compass Pathways' Outlook

Kabir Nath, CEO of Compass Pathways, stated the company is preparing for a potential launch by the end of the year, viewing the voucher as a positive development. The company’s stock saw a modest increase following the announcement.

The Need for New Mental Health Treatments

The FDA’s action comes as mental illness rates remain high in the U.S. Data from the National Alliance on Mental Illness shows that 23.4% of U.S. adults were affected by mental illness in 2024, and 17.6% of veterans experienced similar challenges in 2023.

How Psychedelics Work

These psychedelic treatments work by activating proteins on nerve cells, enhancing the brain’s neuroplasticity – its ability to form new connections. This neuroplasticity is believed to be key to their therapeutic effects.

Potential Risks and Future Outlook

While promising, these treatments carry potential risks, including anxiety, panic attacks, and confusion, requiring careful monitoring. Despite former President Trump’s support for ibogaine, it was not initially included in the voucher program, though a clinical trial for a derivative is underway for alcohol-use disorder.

Experts believe the FDA’s focus on psilocybin is due to its more advanced clinical development. Michael Thase, a professor of psychiatry, suggests ibogaine may become eligible for priority review in the future.